AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
February 27, 2023 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan...
AnaptysBio Announces Stock Repurchase Plan
January 13, 2023 09:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
January 05, 2023 16:05 ET
|
AnaptysBio, Inc.
Advancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to...
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
December 02, 2022 09:00 ET
|
AnaptysBio, Inc.
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer...
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022 13:56 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio to Participate in Upcoming November Investor Conferences
November 09, 2022 14:10 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
November 08, 2022 16:05 ET
|
AnaptysBio, Inc.
Anticipate Rosnilimab, our anti-PD-1 agonist antibody, top-line data in the ongoing AZURE Phase 2 trial in moderate-to-severe alopecia areata in Q1 2023Anticipate ANB032, our anti-BTLA agonist...
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
October 05, 2022 09:00 ET
|
AnaptysBio, Inc.
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of JEMPERLI plus...
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
September 12, 2022 07:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
August 31, 2022 16:15 ET
|
AnaptysBio, Inc.
Imsidolimab (anti-IL-36 receptor antagonist) did not demonstrate improvement over placebo in the primary endpoint and key secondary endpointsImsidolimab was safe and well tolerated with no...